Intelligence Feed event · Policy · 2026-09-09

    CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump

    Question

    CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump

    Direct answer

    CRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-expands-casgevy-pediatric-label-after-78-qoq-sales-jump-317509

    POLICY
    CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
    CRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy.
    CRSPVRTX
    Impact
    69
    SEP 9
    SIG
    87%
    CRSPVRTX
    CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
    CRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy.
    → FDA pediatric label approval for Casgevy down to age 2 broadens the eligible addressable patient population following 78% quarter-over-quarter sales expansion to $76 million for CRISPR Therapeutics.
    Impact
    CRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy.
    Affected
    CRSPVRTX
    Transmission
    FDA pediatric label approval for Casgevy down to age 2 broadens the eligible addressable patient population following 78% quarter-over-quarter sales expansion to $76 million for CRISPR Therapeutics.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial product revenue growth and expanded FDA label indicationUp1-4wCasgevy generated $76M in sales with 78% QoQ growth and received FDA pediatric label approval.
    VRTXcommercial partnership revenue sharing on Casgevy distributionUp1-4wVertex Pharmaceuticals co-develops and commercializes Casgevy alongside CRISPR Therapeutics.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month